Product: FBXL14 Antibody
Catalog: DF13005
Description: Rabbit polyclonal antibody to FBXL14
Application: WB IHC
Cited expt.: WB
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 46 kDa; 46kD(Calculated).
Uniprot: Q8N1E6
RRID: AB_2845966

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)
Clonality:
Polyclonal
Specificity:
FBXL14 Antibody detects endogenous levels of total FBXL14.
RRID:
AB_2845966
Cite Format: Affinity Biosciences Cat# DF13005, RRID:AB_2845966.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Immunogens

Immunogen:

A synthesized peptide derived from human FBXL14, corresponding to a region within the internal amino acids.

Uniprot:
Gene(ID):
Sequence:
METHISCLFPELLAMIFGYLDVRDKGRAAQVCTAWRDAAYHKSVWRGVEAKLHLRRANPSLFPSLQARGIRRVQILSLRRSLSYVIQGMANIESLNLSGCYNLTDNGLGHAFVQEIGSLRALNLSLCKQITDSSLGRIAQYLKGLEVLELGGCSNITNTGLLLIAWGLQRLKSLNLRSCRHLSDVGIGHLAGMTRSAAEGCLGLEQLTLQDCQKLTDLSLKHISRGLTGLRLLNLSFCGGISDAGLLHLSHMGSLRSLNLRSCDNISDTGIMHLAMGSLRLSGLDVSFCDKVGDQSLAYIAQGLDGLKSLSLCSCHISDDGINRMVRQMHGLRTLNIGQCVRITDKGLELIAEHLSQLTGIDLYGCTRITKRGLERITQLPCLKVLNLGLWQMTDSEKEARGDFSPLFTVRTRGSSRR

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Dog
100
Xenopus
100
Chicken
100
Rabbit
100
Horse
56
Sheep
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Substrate-recognition component of some SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin-protein ligase complexes. The SCF(FBXL14) complex acts by mediating ubiquitination and subsequent degradation of SNAI1.

Subcellular Location:

Cytoplasm.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location

References

1). SIRT1 Stabilizes β-TrCP1 to Inhibit Snail1 Expression in Maintaining Intestinal Epithelial Integrity to Alleviate Colitis. Cellular and molecular gastroenterology and hepatology, 2024 (PubMed: 38729522) [IF=7.1]

Application: WB    Species: human    Sample: Caco2 cells

Figure 3. SIRT1 deacetylates and stabilizes β-TrCP1 protein to downregulate Snail1. (A) Caco2 cells stably expressing shRNAs against SIRT1 were subjected to Western blotting. (B) Caco2 cell lysates were subjected to immunoprecipitation (IP) with anti-β-TrCP1, using normal mouse or rabbit IgG as a control, followed by Western blot analyses. (C) Caco2 cells stably coexpressing β-TrCP1 and shRNAs against SIRT1 were subjected to Western blotting. (D) Caco2 cells treated with or without DSS were subjected to Western blotting. (E) HCT116 cells were treated with 4% DSS for 8 hours and the whole cell lysates were subjected to Western blotting. (F) Caco2 cells stably overexpressing SIRT1 were treated with 4% DSS for 8 hours. Whole-cell lysates were subjected to Western blotting. (G) Caco2 cells stably overexpressing β-TrCP1 were treated with 4% DSS for 8 hours. Whole-cell lysates were subjected to Western blotting. (H) Caco2 cells pretreated with 4% DSS for 8 hours or stably expressing shRNAs against SIRT1 were subjected to qPCR analyses for β-TrCP1. (I) To examine the effects of DSS on ubiquitination of β-TrCP1, 293FT cells were cotransfected with the relevant expression plasmids for 48 hours, followed by treatment with 4% DSS for 12 hours. Before harvesting, cells underwent treatment with 20 μM MG132 for 6 hours. Ubiquitination of β-TrCP1 was examined by denature-IP-western analyses. (J) The β-TrCP1 protein half-lives were measured by CHX assays in Caco2 cells pretreated with 4% DSS for 8 hours. (K and L) To examine the effects of SIRT1 on ubiquitination of β-TrCP1 and Snail1, 293FT cells were cotransfected with indicated expressing plasmids. Cells were treated with 20 μM MG132 for 6 hours before collection. Ubiquitination of Snail1 was examined by denature-IP-western analyses. (M) The β-TrCP1 and Snail1 protein half-lives were measured by CHX assays in Caco2 cells stably overexpressing SIRT1. (N and O) Caco2 cell lysates were subjected to IP with anti-SIRT1 (H) or anti-β-TrCP1 (I), using normal mouse or rabbit IgG as a control, followed by Western blot analyses. (P) HEK-293T cells cotransfected with His/Myc-β-TrCP1 and Flag-SIRT1 were subjected to IP and Western blotting analyses.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.